ElectroCore opened lower at $7.67, compared with its previous close of $7.71. In the last trading session, the stock traded between $4.92 and $7.92. It showed a downward intraday trend.
An investment of $100 made 5 years ago in ElectroCore is now worth
$ 37.35
Resulting in a loss of
$ 62.65 (62.65%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-2.49 (-32.27%)
Day High
$7.92
Day Low
$4.92
Day Open
$7.67
Prev Close
$7.71
Volume
5,98,657
1W Return
-37.39%
1M Return
-42.59%
3M Return
-42.39%
6M Return
-21.00%
1Y Return
-17.11%
Market Cap ($ Mn)
48
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-681.93%
ROCE
-166.58%
EPS (TTM)
$-0.15
1 Week
-37.39%
1 Month
-42.59%
3 Months
-42.39%
6 Months
-21.00%
9 Months
-4.36%
electroCore sees FY27 revenue growth of 30% to 40% YoY
electroCore Inc introduced FY27 revenue guidance of 30% to 40% YoY growth. FY26 sales guidance remains widened to a range of $39.0 million to $42.0 million. Previous FY26 single-point estimate was $41.6 million, close to analyst consensus of $41.915 million.
8 days agoelectroCore Q2FY26 Results: Revenue up 28% to $9.5 million
Revenue rose 28% YoY to $9.5 million, driven by VA prescription sales and Quell product growth. Full-year 2026 revenue guidance raised to greater than 30% growth following sales force restructuring. GAAP net loss narrowed 17% to $3.1 million; adjusted EBITDA loss improved 26% YoY to $1.8 million. Gross margin contracted to 86.5% from 87.3% due to higher inventory reserves despite $1.7 million gross profit increase. Company targets positive adjusted EBITDA by Q3 2027 with $10 million cash on hand.
1mo agoelectroCore's Truvaga named best luxury biohacking brand in USA
electroCore's Truvaga named 2026 Best Luxury Biohacking Brand by Luxury Lifestyle Awards. Recognition cites patented non-invasive vagus nerve stimulation technology and design. Devices support relaxation and stress management via two-minute sessions. Company offers one-on-one consultations and educational resources for users.
2mo agoelectroCore lowers FY26 sales guidance to $41.6M vs estimate
electroCore has reduced its FY2026 sales guidance to $41.600 million, down from $41.642 million previously stated. The revised figure misses the market estimate of $41.921 million, marking a slight negative deviation from analyst expectations.
3mo agoelectroCore Q2 Results: EPS beats estimates, sales rise 28% YoY
electroCore delivered better-than-expected earnings per share of $(0.33) in Q2, beating the $(0.40) estimate by 17.5 percent. Sales rose 28.03 percent year-over-year to $9.450 million, narrowly missing the $9.491 million consensus. The results reflect a significant narrowing of losses compared to the prior year.
3mo agoelectroCore review article accepted by Frontiers in Neuroscience
electroCore, Inc. announced the acceptance of its review article on cervical nVNS by Frontiers in Neuroscience. The article synthesizes evidence from multiple disciplines to support vagal activation without surgery. Key products include gammaCore® and Quell® Fibromyalgia, along with wellness-focused Truvaga™ and TAC-STIM™.
5mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in ElectroCore is now worth
$ 37.35
Resulting in a loss of
$ 62.65 (62.65%)
Note: Past profits do not guarantee future returns.
